logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

ABBISKO-B (02256) repurchased 50,000 shares on October 21 for HK$376,200.

date
21:05 21/10/2026
avatar
GMT Eight
ABBISKO-B (02256) announced that on October 21, 2026, it repurchased 50,000 shares for HK$376,200.
ABBISKO-B (02256) announced that on October 21, 2026, it repurchased 50,000 shares for HK$376,200.
Related Articles
Far exceeds expectations! Super Micro Computer, Inc. (SMCI.US) quarterly revenue approaches $19.5 billion, Wall Street hails it as a "clear positive signal"
HK Stock
MINSHENG EDU (01569) has been granted a revolving loan of up to RMB 300 million.
China Stock
Shanghai Yizhong Pharmaceutical (688091.SH): First dosing of the first dose cohort completed in Phase I clinical trial of innovative drug YXC-001
Far exceeds expectations! Super Micro Computer, Inc. (SMCI.US) quarterly revenue approaches $19.5 billion, Wall Street hails it as a "clear positive signal"
MINSHENG EDU (01569) has been granted a revolving loan of up to RMB 300 million.
HK Stock
Shanghai Yizhong Pharmaceutical (688091.SH): First dosing of the first dose cohort completed in Phase I clinical trial of innovative drug YXC-001
China Stock
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.